Journal of clinical oncology, 40(4), 382-391. American Society of Clinical Oncology Adenis, A, Kulkarni, A S, Girotto, G C, de la Fouchardiere, C, Senellart, H, van Laarhoven, H W M, Mansoor, W, Al-Rajabi, R, Norquist, J, Amonkar, M, Suryawanshi, S, Bhagia, P & Metges, J-P 2022, ' Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181 ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 40, no. 4, pp. 382-391 . https://doi.org/10.1200/JCO.21.00601 Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 40(4), 382-391. American Society of Clinical Oncology
Gastric Cancer Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, vol 24, iss 6
Andre, T, Amonkar, M, Norquist, J M, Shiu, K-K, Kim, T W, Jensen, B V, Jensen, L H, Punt, C J A, Smith, D, Garcia-Carbonero, R, Sevilla, I, De La Fouchardiere, C, Rivera, F, Elez, E, Diaz, L A, Yoshino, T, Van Cutsem, E, Yang, P, Farooqui, M & Le, D T 2021, ' Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177) : an open-label, randomised, phase 3 trial ', The Lancet Oncology, vol. 22, no. 5, pp. 665-677 . https://doi.org/10.1016/S1470-2045(21)00064-4 lancet oncology, 22(5), 665-677. Lancet Publishing Group